Let’s ask a trick question. 

Do you think your organization’s data is ready for AI, or AI Agents?

Most sponsors and CROs instinctively answer “not yet.” What this really means is that they don’t believe their data isn’t fully centralized, dictionaries aren’t perfectly aligned, and too many systems still operate in parallel. The result is that AI gets parked on the roadmap, waiting for a future state where everything is clean, standardized, and coordinated.

Here’s the twist; waiting for that moment is very thing holding organizations back.

When it comes to implementing agentic AI, the bigger risk right now isn’t imperfect data. Instead, it’s waiting for perfection before acting.

‍

To many, the SCOPE Summit is the year’s “newsroom,” setting the stage for what hot topics and driving forces will dominate the coming year. 

With this year’s conference winding down, we’re once again offering a glimpse into the evolving operational and technological conversations shaping the future of trials with our recap below.  

‍

eCOA has moved from a supporting tool to a foundational pillar of modern clinical trials, and Everest Group agrees. In its inaugural eCOA Products PEAK Matrix Assessment, Everest named Medable a Leader, citing strong market impact, accelerated timelines, and a platform built for real-world trial complexity. As the eCOA market surges toward nearly $1B in value, this recognition underscores how speed, patient experience, and AI-driven innovation are reshaping how trials are designed, launched, and scaled globally.

‍